Ocular Therapeutix (OCUL) interim CFO receives 33,000 stock options grant

Rhea-AI Filing Summary

Ocular Therapeutix interim CFO Jason Shand Robins reported receiving a stock option grant linked to common shares of the company. On January 20, 2026, he was awarded a stock option to buy 33,000 shares of Ocular Therapeutix common stock at an exercise price of $11.45 per share. The filing shows he beneficially owns 33,000 derivative securities directly after this grant. The option vests over four years, with 1/48 of the underlying shares vesting monthly beginning one month after the grant date, conditioned on his continued service to the corporation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Robins Jason Shand

Role Interim CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	33,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 33,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robins Jason Shand

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.45	01/20/2026		A		33,000		(1)	01/19/2036	Common Stock	33,000	$0	33,000	D

Explanation of Responses:

1. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

	/s/ Todd Anderman, Attorney-in-Fact for Jason Shand Robins	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OCUL interim CFO Jason Shand Robins report?

He reported the grant of a stock option (right to buy) on January 20, 2026, covering 33,000 shares of Ocular Therapeutix common stock.

How many Ocular Therapeutix (OCUL) options were granted to the interim CFO?

The interim CFO was granted 33,000 stock options, with 33,000 derivative securities shown as beneficially owned directly after the transaction.

What is the exercise price of the OCUL stock options granted to the interim CFO?

The stock option granted to the interim CFO has an exercise price of $11.45 per share for Ocular Therapeutix common stock.

How do the OCUL options granted to the interim CFO vest?

According to the footnote, the shares underlying the option vest over four years, with 1/48 of the shares vesting monthly starting on the one-month anniversary of the grant date, subject to his continued service.

Is the OCUL option grant to the interim CFO reported as direct or indirect ownership?

The filing reports direct (D) ownership of 33,000 derivative securities by the interim CFO following the transaction.

What role does the reporting person hold at Ocular Therapeutix (OCUL)?

The reporting person, Jason Shand Robins, is listed as an officer of Ocular Therapeutix with the title Interim CFO.